Phase 3 N=147 Randomized Treatment

Comparison of Three Different Pain Blocks for Subjects Undergoing VATS (Video Assisted Thoracoscopic Surgery) Procedure.

Video Assisted Thoracoscopic Surgery · Pain, Postoperative · Pain, Acute

Bottom Line

View on ClinicalTrials.gov: NCT03151434 ↗

Enrolled (actual)

147

Serious AEs

0.0%

Results posted

Jan 2021

Primary outcome: Primary: The Primary Endpoint of This Study Will be VAS Pain Score at 24 Hours — 4.0; 4.5; 3.0 units on a scale

Study Design & Population

Study type: Interventional
Phase: Phase 3
Interventions: US Guided Single Shot Paravertebral Block (0.2% ropivicaine infusion) (Drug); US Guided Paravertebral Catheter (0.2% ropivicaine bolus) (Drug); Thoracic Epidural (0.125% bupivicaine/hydromorphone) (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Indiana University
Primary completion: Jul 2018

Outcome Measures

Outcome	Result	p-value
PRIMARY The Primary Endpoint of This Study Will be VAS Pain Score at 24 Hours	4.0; 4.5; 3.0	—
PRIMARY The Primary Endpoint of This Study Will be VAS Pain Score at 48 Hours	3.0; 4.0; 2.0	—
SECONDARY Secondary Endpoint Includes Total Intravenous Opioid Consumption at 72 Hours	57; 35; 21.3	—

Summary

The purpose of this study is to compare three different pain control methods on subjects who are scheduled to undergo VATS (video-assisted thoracoscopic surgery) procedures. The study will compare their pain scores, narcotic needs, patient satisfaction scores, and narcotic side effects.

Eligibility Criteria

Inclusion Criteria

Pt undergoing VATS procedure at Indiana University Hospital
ASA 1,2,3 or 4
Age 18 or older, male or female
Desires Regional anesthesia for postoperative pain control

Exclusion Criteria

Any contraindication for Thoracic Epidural or Paravertebral block
History of substance abuse in the past 6 months
Patient staying intubated after surgery
Known allergy or other contraindications to the study medications , which include dilaudid, bupivacaine, ropivacaine

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03151434). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.